FIH Partners advises Novo Holdings on the proposed merger between Novozymes, and Chr. Hansen. The merger will leverage Novozymes’ and Chr. Hansen’s combined expertise, powerful capabilities, and innovation and commercial excellence to develop biological solutions that will enable healthier lives, transform food systems and accelerate the journey towards a climate neutral society.
The proposed combination of Novozymes and Chr. Hansen will create a strong biosolutions group with a broad biological toolbox and a diversified portfolio across markets. Uniting two strategically complementary companies will accelerate their already best-in-class performance.
The merged entity would have combined annual revenue of EUR ~3.5bn, EBITDA of EUR ~1.2bn and EBIT of EUR ~0.9bn as of 30th September 2022. The transaction is expected to generate EBIT synergies in the range of EUR 160-180m and is expected to close during Q4 2023/Q1 2024.
FIH Partners acted as exclusive M&A advisor to Novo Holdings on the transaction.
